Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letters to Editor
  • Published:

New Look at Antiserum Therapy of Leukaemia

Abstract

ANTIBODY complexed to target cells can induce killing of the target cell by certain non-immune lymphoid cells. Several studies (see refs 1–3 for recent reviews) have shown that antibody having this activity (“lymphocyte” dependent antibody or LDA) is of the IgG class and that the effector cells are thymus-independent cells4 bearing receptors for the Fc portion of IgG on their surface. Examples of this cytotoxic mechanism in vitro have now been described in xeno-, allo- and autoimmune situations1–3. More recent reports have implicated the mechanism in tumour rejection5–7 and LDA activity has been described in vitro against allogeneic myeloblasts8 and transplantation antigens in man9.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

HERSEY, P. New Look at Antiserum Therapy of Leukaemia. Nature New Biology 244, 22–24 (1973). https://doi.org/10.1038/newbio244022a0

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1038/newbio244022a0

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing